FASN and breast carcinoma: Cancer cells can also rewire lipid metabolism to mediate the development of acquired drug resistance [17], while targeting lipid metabolic enzymes (e.g., fatty acid synthase) re-sensitize breast cancer resistant to HER2-targeted therapies [18].